Restless Legs Syndrome
Conditions
Brief summary
The primary objective of this trial is to assess the efficacy of XP13512 taken once daily compared to placebo for the treatment of patients suffering from Restless Legs Syndrome (RLS).
Detailed description
This was a 12-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy and safety of XP13512 in subjects with Restless Legs Syndrome (RLS). Eligible subjects were randomized to receive 1 of 3 once daily oral doses of XP13512 1200 mg, XP13512 600 mg, or placebo. The primary study objective was to compare the efficacy of XP13512 1200 mg taken once daily for 12 weeks versus placebo. The secondary study objectives were to assess the efficacy of XP13512 600 mg taken once daily for the reatment of RLS and to assess the onset of treatment benefits and improvement in sleep, pain, mood, quality of life, and safety and tolerability of both XP13512 1200 mg and 600 mg.
Interventions
DRUGXP13512 600MG
XP13512 600MG ONCE DAILY
DRUGXP13512 1200MG
XP13512 1200MG ONCE DAILY
DRUGPLACEBO
PLACEBO ONCE DAILY
Sponsors
XenoPort, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with primary RLS, based on the International RLS Study Diagnostic Criteria.
Exclusion criteria
* A sleep disorder (e.g., sleep apnea) that may significantly affect the assessment of RLS; * Neurologic disease or movement disorder (e.g., diabetic neuropathy, Parkinson's Disease, Multiple Sclerosis, dyskinesias, and dystonias); * Abnormal laboratory results, electrocardiogram (ECG) or physical findings; * Pregnant or lactating women; * Women of childbearing potential who are not practicing an acceptable method of birth control.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline in IRLS Rating Scale Total Score at Week 12 Using Last Observation Carried Forward (LOCF) | Baseline and Week 12 | The International Restless Legs Syndrome (IRLS) Rating scale is a measure of RLS disease severity. The scale reflects the participant-reported assessment of primary sensory and motor features and associated sleep problems in RLS. Ten items (individually scored from 0 to 4) are included that assess the impact of symptoms on participants' mood, daily life, and activities. The total scale score is a sum of all of the individual item scores and ranges from 0-40 points, with 40 being the most severe. The scale assesses symptoms over the week prior to measurement. |
| Number of Participants With a Score of Much Improved or Very Much Improved on the Investigator-rated CGI-I Scale (Response) at (Week 12) Using LOCF | Week 12 | The investigator -rated Clinical Global Impression of Improvement (CGI-I) scale is an assessment designed to allow investigators to rate the change of a participant's disease severity over time based on a seven-point scale, with a score of 1 being very much improved, a score of 2 being much improved, a score of 3 being minimally improved, a score of 4 being no change, a score of 5 being minimally improved,a score of 6 being much worse, and a score of 7 being very much worse. Participants with a response of much improved or very much improved were classified as responders. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants Who Had an Onset of Response to Treatment at the End of Week 1 Based Upon the IRLS Rating Scale Total Score and the Investigator-rated CGI-I Using LOCF | End of Week 1 | The IRLS Rating scale is a measure of RLS disease severity. Items (individually scored from 0 to 4) are included that assess the impact of symptoms on participants' mood, daily life, and activities. The total scale score is a sum of all of the individual item scores and ranges from 0-40 points, with 40 being the most severe. Response was defined by an IRLS Rating Scale total score at the end of Week 1 \< 15 and at least a 6-point reduction from the participant's Baseline score and an investigator-rated CGI-I response of much improved or very much improved. |
| The Time to Onset of the First Response to Treatment on the IRLS Rating Scale Total Score and the Investigator-rated CGI-I | Baseline (Day 1) to End of Treatment (Week 12) | The Response was defined by an IRLS Rating Scale total score at the end of Week 1 \< 15 and at least a 6-point reduction from the participant's Baseline score and an investigator-rated CGI-I response of much improved or very much improved. The median time to onset is estimated using the product-limit estimation method. |
| Mean Change in the IRLS Rating Scale Total Score From Baseline at Week 12 by RLS Treatment History Using LOCF | Baseline (Day 1) and Week 12 | The IRLS Rating scale is a measure of RLS disease severity. The scale reflects the participant-reported assessment of primary sensory and motor features and associated sleep problems in RLS. Ten items (individually scored from 0 to 4) are included that assess the impact of symptoms on participants' mood, daily life, and activities. The total scale score is a sum of all of the individual item scores and ranges from 0-40 points, with 40 being the most severe. The scale assesses symptoms over the week prior to measurement. |
| Change From Baseline in the IRLS Rating Scale Total Score at Week 12 by Baseline RLS Rating Scale Total Score Category (Baseline RLS Severity) Using LOCF | Baseline (Day 1) and Week 12 | The IRLS Rating scale is a measure of RLS disease severity. The scale reflects the participant-reported assessment of primary sensory and motor features and associated sleep problems in RLS. Ten items (individually scored from 0 to 4) are included that assess the impact of symptoms on participants' mood, daily life, and activities. The total scale score is a sum of all of the individual item scores and ranges from 0-40 points, with 40 being the most severe. The scale assesses symptoms over the week prior to measurement. |
| Change From Baseline to the End of Week 1 in the IRLS Rating Scale Total Score Using LOCF | Baseline and the End of Week 1 | The IRLS Rating scale is a measure of RLS disease severity. The scale reflects the participant-reported assessment of primary sensory and motor features and associated sleep problems in RLS. Items (individually scored from 0 to 4) are included that assess the impact of symptoms on participants' mood, daily life, and activities. The total scale score is a sum of all of the individual item scores and ranges from 0-40 points, with 40 being the most severe. The scale assesses symptoms over the week prior to measurement. |
| Number of Participants Classified as Investigator-rated CGI-I Scale Responders at Week 12 by RLS Treatment History Using LOCF | Basline and Week 12 | The CGI-I scale is a standardized tool that is widely used in psychopharmacologic trials. For the CGI-I, the investigator was asked to rate the participant's overall change in RLS symptoms from Baseline. Scores ranged from 1 (very much improved) to 7 (very much worse). Participants who were much improved (score of 2) or very much improved on the CGI-I scale at the end of treatment (Week 12) are classified as Responders. |
| Number of Total Responders to Treatment Based on the Investigator-Rated CGI of Improvement at the End of One Week of Treatment | End of Week 1 | The CGI-I scale is a standardized tool that is widely used in psychopharmacologic trials. For the CGI-I, the investigator was asked to rate the participant's overall change in RLS symptoms from Baseline. Scores ranged from 1 (very much improved) to 7 (very much worse). Participants who were much improved (score of 2) or very much improved on the CGI-I scale at the end of treatment (Week 12) are classified as Responders. |
| Change From Baseline to the End of Treatment in Average Daily Total Sleep Time (Hours) Using LOCF | Baseline to End of Treatment (Week 12) | Average daily total sleep time was derived from the Pittsburgh Sleep Diary (PghSD; an instrument with separate components to be completed \[self-reported\] at bedtime and waketime) as the mean of non-missing total sleep time over the 7 days before each visit, where total sleep time = \[(wake up time - lights out time) - time to fall asleep - time awake during the night\] in hours. The change was calculated as the end of treatment (Week 12) value minus the Baseline value. |
| Change From Baseline to the End of Treatment in Average Daily Wake Time (Minutes) After Sleep Onset Using LOCF | Baseline to End of Treatment (Week 12) | Average daily wake time after sleep onset was derived from the Pittsburgh Sleep Diary (PghSD) as the mean of non-missing total hours awake during the night after falling asleep over the 7 days before each visit. The change was calculated as the end of treatment (Week 12) value minus the Baseline value. |
| Change From Baseline in the Average Daily RLS Pain Score at the End of Treatment (Week 12) for Participants With Pain at Baseline or the End of Week 12 Using LOCF | Baseline and End of Treatment (Week 12) | The Daily RLS pain score was assessed by participants reporting whether they experienced any pain associated with RLS in the last 24 hours and rating their pain levels on an 11-point numerical rating scale, with 0 being no pain and 10 the most intense pain imaginable. The assessment was performed for 7 days prior to Baseline and pre-defined study visits. The change from baseline was calculated as the End of Treatment (Week 12) value minus the Baseline (Day 1) value. |
| Number of Participants Classified as Responders With at Least 30% and 50% Improvement in the Average Daily RLS Pain Score Using LOCF | Week 12 | The Mean Daily RLS pain was assessed by participants reporting whether they experienced any pain associated with RLS in the last 24 hours and rating their pain levels on an 11-point numerical rating scale, with 0 being no pain and 10 the most intense pain imaginable. The assessment was performed for 7 days prior to Baseline and pre-defined visits A Responder is a participant with a score of much improved or very much improved on the investigator rated CGI I Scale at the end of treatment (Week 12 using LOCF). |
| Change From Baseline to the End of Treatment (Week 12) in the IRLS Rating Scale Total Score Using LOCF | Baseline (Day 1) and End of Treatment (Week 12) | The IRLS Rating scale is a measure of RLS disease severity. The scale reflects the participant-reported assessment of primary sensory and motor features and associated sleep problems in RLS. Items (individually scored from 0 to 4) are included that assess the impact of symptoms on participants' mood, daily life, and activities. The total scale score is a sum of all of the individual item scores and ranges from 0-40 points, with 40 being the most severe. The scale assesses symptoms over the week prior to measurement. |
| Number of Participants Classified as Responders to Treatment Based on the Participant-Rated CGI of Improvement at Week 1 and Week 12 (End of Treatment) | Week 1 and Week 12 | The CGI-I scale is a standardized tool that is widely used in psychopharmacologic trials. For the CGI-I, the investigator was asked to rate the participant's overall change in RLS symptoms from Baseline. Scores ranged from 1 (very much improved) to 7 (very much worse). Participants who were much improved (score of 2) or very much improved on the CGI-I scale at the end of treatment (Week 12) are classified as Responders. |
| Number of Participants With a Rating of Excellent for the Overall Quality of Sleep in Past Week Measured by the Post-Sleep Questionnaire (PSQ) at the End of Treatment (Week 12) Using LOCF | End of Treatment (Week 12) | The Post-Sleep Questionnaire (PSQ) was designed to evaluate overall sleep quality, ability to function, and RLS symptoms' interference with sleep over the past week. Participants were asked to rate overall sleep quality (as either Excellent, Reasonable, or Poor), ability to function, number of nights with RLS symptoms, number of nights awakened by RLS symptoms, and the number of hours spent awake due to RLS symptoms over the past week. |
| Number of Participants Who Indicated on the Mood Assessment That Their Mood Was Much Improved or Very Much Improved at Week 12 (End of Treatment) Using LOCF | Week 12 | The Mood Assessment is a non-disease-specific question surveying global change in a participant's overall mood. Participants were asked to rate their overall change in mood since the start of the study by choosing a score in a range from 1 (Very Much Improved) to 7 (Very Much Worse). The assessment was completed at Day 1 and the ends of Weeks 4, 8, and 12 or (Early Termination). |
| Change From Baseline in the Profile of Mood State (POMS) Scale at Week 12 Using LOCF | Baseline to End of Treatment (Week 12) | The Profile of Mood States (POMS) Brief Form contains 30 adjectives; each participant is asked to rate the degree to which each adjective describes themselves based on how they felt during the past week including the date on which the adjective was rated. The possible ratings range from 0 (Not all all) to 4 (Extremely). The Total Mood Disturbance Score (range of 0 to 120) is obtained by summing the values of six domains. Higher scores indicate a more negative mood disturbance. The POMS was completed at Baseline (Day 1), and at the end of Weeks 4, 8, and 12 (or Early Termination). |
| Change From Baseline in the Daytime Somnolence Score, an Item on the Medical Outcomes Study (MOS) Sleep Scale, at Week 12 Using LOCF | Baseline and Week 12 | The MOS Sleep Scale measures most constructs of sleep. The scale has a battery of questions to measure specific aspects of sleep in participants with co-morbidities. The four domains scored from the MOS Sleep Scale were sleep disturbance,' sleep quantity,' sleep adequacy, and daytime somnolence. The scores of the daytime somnolence domain ranged from 1 to 100, with a high score indicating greater daytime somnolence. The assessment was completed at Baseline (Day 1) and end of Weeks, 4, 8, and 12 (or end of Treatment). |
| Change From Baseline in the Sleep Disturbance Score, an Item on the MOS Sleep Scale, at Week 12 Using LOCF | Baseline and Week 12 | The MOS Sleep Scale measures most constructs of sleep. The scale has a battery of questions to measure specific aspects of sleep in participants with co-morbidities. The four domains scored from the MOS Sleep Scale were sleep disturbance,' sleep quantity,' sleep adequacy, and daytime somnolence. The scores of the sleep disturbance domain ranged from 1 to 100, with a high score indicating greater impairment of sleep. The assessment was completed at Baseline (Day 1) and end of Weeks, 4, 8, and 12 (or end of Treatment). |
| Change From Baseline in Sleep Adequacy, an Item on the MOS Sleep Scale, at Week 12 Using LOCF | Basline and Week 12 | The MOS Sleep Scale measures most constructs of sleep. The scale has a battery of questions to measure specific aspects of sleep in participants with co-morbidities. The four domains scored from the MOS Sleep Scale were sleep disturbance,' sleep quantity,' sleep adequacy, and daytime somnolence. The scores of the sleep adequacy domain ranged from 1 to 100, with a high score indicating greater adequacy. The assessment was completed at Baseline (Day 1) and end of Weeks, 4, 8, and 12 (or end of Treatment). |
| Change From Baseline in Sleep Quantity, an Item on the MOS Sleep Scale, at Week 12 Using LOCF | Baseline and Week 12 | The MOS Sleep Scale measures most constructs of sleep. The scale has a battery of questions to measure specific aspects of sleep in participants with co-morbidities. The four domains scored from the MOS Sleep Scale were sleep disturbance,' sleep quantity,' sleep adequacy, and daytime somnolence. The scores of the sleep quantity domain were measured in time (number of hours of sleep each night). The assessment was completed at Baseline (Day 1) and end of Weeks, 4, 8, and 12 (or end of Treatment). |
| Change From Baseline in the Overall Life-Impact Score of the RLS Quality of Life (QoL) Questionnaire at Week 12 Using LOCF | Baseline and Week 12 | The Restless Legs Syndrome Quality of Life (RLS-QoL) questionnaire is a disease-specific, participant-rated questionnaire that assesses the impact of RLS on daily life, emotional well-being, social life, and work life of the participants. The RLS-QoL Questionnaire is presented on a 0 (lowest possible score) to 100 (highest possible score) scale. It was completed at Day 1 and at the end of Weeks 4, 8, and 12 (or Early Termination). |
| Number of Participants Experiencing No RLS Symptoms in Each of the Seven 4-hour Periods From the 24-hour RLS Record at Week 12 (End of Treatment) | Week 12 | RLS severity ratings were summarized in 6 non-overlapping 4-hour periods beginning at 8 AM. A 4-hour period from 6 PM to 10 PM was also prospectively included to reflect the time frame when the most participants would experience their first symptoms of the day. |
| Time to Onset of the First RLS Symptom From the 24-hour RLS Record Obtained at the End of Treatment (Week 12) | Week 12 | The time to onset of the first RLS symptoms from the 24-hour RLS Record is defined as the length of time from the start of the 24-hour assessment period (8:00 AM) to the time when 50% of participants experienced their first symptom. |
| Change From Baseline in the Average Daily RLS Pain Score to Week 12 for Participants With a Baseline Pain Score of at Least 4 Using LOCF | Baseline and Week 12 | The Average Daily RLS pain was assessed by participants reporting whether they experienced any pain associated with RLS in the last 24 hours and rating their pain levels on an 11-point numerical rating scale, with 0 being no pain and 10 the most intense pain imaginable. The assessment was performed for 7 days prior to Baseline and pre-defined visits. The change from baseline was calculated as the End of Treatment (Week 12) value minus the Baseline (Day 1) value. |
| Number of Participants Classsified as Responders on the Investigator-rated CGI-I Scale at Week 12 Using LOCF | Week 12 | The CGI-I scale is a standardized tool that is widely used in psychopharmacologic trials. For the CGI-I, the investigator was asked to rate the participant's overall change in RLS symptoms from Baseline. Scores ranged from 1 (very much improved) to 7 (very much worse). Participants who were much improved (score of 2) or very much improved on the CGI-I scale at the end of treatment (Week 12) are classified as Responders. |
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Placebo Oral placebo tablet taken once daily. Days 1 to 3: one placebo tablet. Days 4 to 84: two placebo tablets. On Days 85 participants entered a 7-day Taper Period. Days 85 to 91: one placebo tablet. | 96 |
| GEn (XP13512/GSK1838262) 600 mg Gabapentin enacarbil (GEn) (XP13512/GSK1838262) 600 milligrams (mg) taken orally once a day for 12 weeks) taken once daily. Days 1 to 3: one extended release (ER) tablet (600 mg GEn). Days 4 to 84: one ER tablet (600 mg GEn) and one placebo tablet. On Day 85, participants entered a 7-day Taper Period. Days 85 to 91: one placebo tablet. | 114 |
| GEn (XP13512/GSK1838262) 1200 mg Oral GEn (gabapentin enacarbil) 1200 milligrams (mg) taken once daily. Days 1 to 3: one extended release (ER) tablet (600 mg GEn). Days 4 to 84: two ER tablets (1200 mg GEn). On Day 85, participants entered a 7-day Taper Period. Days 85 to 91: one ER tablet (600 mg GEn). | 111 |
| Total | 321 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Overall Study | Adverse Event | 6 | 7 | 8 |
| Overall Study | Ineligible (Did Not Meet Entry Criteria) | 0 | 0 | 2 |
| Overall Study | Lack of Efficacy | 3 | 0 | 0 |
| Overall Study | Lost to Follow-up | 1 | 1 | 0 |
| Overall Study | Non-Compliance (after Randomization) | 1 | 0 | 1 |
| Overall Study | Participant Withdrew Consent | 8 | 3 | 4 |
| Overall Study | Withdrawal of Participant by Sponsor | 1 | 0 | 0 |
Baseline characteristics
| Characteristic | Placebo | GEn (XP13512/GSK1838262) 600 mg | GEn (XP13512/GSK1838262) 1200 mg | Total |
|---|---|---|---|---|
| Age Continuous | 49.1 Years STANDARD_DEVIATION 12.19 | 48.3 Years STANDARD_DEVIATION 12.88 | 49.5 Years STANDARD_DEVIATION 12.67 | 48.9 Years STANDARD_DEVIATION 12.58 |
| Race/Ethnicity, Customized American Indian or Alaskan Native | 1 participants | 3 participants | 0 participants | 4 participants |
| Race/Ethnicity, Customized Asian | 2 participants | 0 participants | 1 participants | 3 participants |
| Race/Ethnicity, Customized Black or African American | 1 participants | 5 participants | 1 participants | 7 participants |
| Race/Ethnicity, Customized Native Hawaiian or Other Pacific Islander | 1 participants | 0 participants | 0 participants | 1 participants |
| Race/Ethnicity, Customized Unknown | 0 participants | 2 participants | 2 participants | 4 participants |
| Race/Ethnicity, Customized White or Caucasian | 92 participants | 106 participants | 107 participants | 305 participants |
| Sex: Female, Male Female | 57 Participants | 66 Participants | 65 Participants | 188 Participants |
| Sex: Female, Male Male | 39 Participants | 48 Participants | 46 Participants | 133 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — |
| other Total, other adverse events | 36 / 96 | 68 / 115 | 64 / 111 |
| serious Total, serious adverse events | 1 / 96 | 2 / 115 | 0 / 111 |
Outcome results
Primary
Change From Baseline in IRLS Rating Scale Total Score at Week 12 Using Last Observation Carried Forward (LOCF)
The International Restless Legs Syndrome (IRLS) Rating scale is a measure of RLS disease severity. The scale reflects the participant-reported assessment of primary sensory and motor features and associated sleep problems in RLS. Ten items (individually scored from 0 to 4) are included that assess the impact of symptoms on participants' mood, daily life, and activities. The total scale score is a sum of all of the individual item scores and ranges from 0-40 points, with 40 being the most severe. The scale assesses symptoms over the week prior to measurement.
Time frame: Baseline and Week 12
Population: Modified Intent-to-Treat (MITT) Population: all participants in the Safety Population who also satisfied all of the following conditions: (1) completed the IRLS Rating Scale at Baseline; and (2) completed at least one on-treatment IRLS Rating Scale score during the treatment period
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline in IRLS Rating Scale Total Score at Week 12 Using Last Observation Carried Forward (LOCF) | -9.8 scores on a scale | Standard Deviation 7.69 |
| GEn (XP13512/GSK1838262) 1200 mg | Change From Baseline in IRLS Rating Scale Total Score at Week 12 Using Last Observation Carried Forward (LOCF) | -13.0 scores on a scale | Standard Deviation 9.12 |
p-value: 0.001595% CI: [-5.6, -1.3]ANCOVA
Primary
Number of Participants With a Score of Much Improved or Very Much Improved on the Investigator-rated CGI-I Scale (Response) at (Week 12) Using LOCF
The investigator -rated Clinical Global Impression of Improvement (CGI-I) scale is an assessment designed to allow investigators to rate the change of a participant's disease severity over time based on a seven-point scale, with a score of 1 being very much improved, a score of 2 being much improved, a score of 3 being minimally improved, a score of 4 being no change, a score of 5 being minimally improved,a score of 6 being much worse, and a score of 7 being very much worse. Participants with a response of much improved or very much improved were classified as responders.
Time frame: Week 12
Population: MITT Population
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Placebo | Number of Participants With a Score of Much Improved or Very Much Improved on the Investigator-rated CGI-I Scale (Response) at (Week 12) Using LOCF | 43 participants |
| GEn (XP13512/GSK1838262) 1200 mg | Number of Participants With a Score of Much Improved or Very Much Improved on the Investigator-rated CGI-I Scale (Response) at (Week 12) Using LOCF | 86 participants |
p-value: 0.000195% CI: [2.338, 7.861]Regression, Logistic
Secondary
Change From Baseline in Sleep Adequacy, an Item on the MOS Sleep Scale, at Week 12 Using LOCF
The MOS Sleep Scale measures most constructs of sleep. The scale has a battery of questions to measure specific aspects of sleep in participants with co-morbidities. The four domains scored from the MOS Sleep Scale were sleep disturbance,' sleep quantity,' sleep adequacy, and daytime somnolence. The scores of the sleep adequacy domain ranged from 1 to 100, with a high score indicating greater adequacy. The assessment was completed at Baseline (Day 1) and end of Weeks, 4, 8, and 12 (or end of Treatment).
Time frame: Basline and Week 12
Population: MITT Population. The number of participants assessed varies due to incomplete/missing data.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline in Sleep Adequacy, an Item on the MOS Sleep Scale, at Week 12 Using LOCF | 13.6 scores on a scale | Standard Deviation 24.59 |
| GEn (XP13512/GSK1838262) 1200 mg | Change From Baseline in Sleep Adequacy, an Item on the MOS Sleep Scale, at Week 12 Using LOCF | 29.1 scores on a scale | Standard Deviation 29.91 |
| GEn (XP13512/GSK1838262) 1200 mg | Change From Baseline in Sleep Adequacy, an Item on the MOS Sleep Scale, at Week 12 Using LOCF | 27.7 scores on a scale | Standard Deviation 29.91 |
Secondary
Change From Baseline in Sleep Quantity, an Item on the MOS Sleep Scale, at Week 12 Using LOCF
The MOS Sleep Scale measures most constructs of sleep. The scale has a battery of questions to measure specific aspects of sleep in participants with co-morbidities. The four domains scored from the MOS Sleep Scale were sleep disturbance,' sleep quantity,' sleep adequacy, and daytime somnolence. The scores of the sleep quantity domain were measured in time (number of hours of sleep each night). The assessment was completed at Baseline (Day 1) and end of Weeks, 4, 8, and 12 (or end of Treatment).
Time frame: Baseline and Week 12
Population: MITT Population. The number of participants assessed varies due to incomplete/missing data.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline in Sleep Quantity, an Item on the MOS Sleep Scale, at Week 12 Using LOCF | 0.3 hours | Standard Deviation 1.19 |
| GEn (XP13512/GSK1838262) 1200 mg | Change From Baseline in Sleep Quantity, an Item on the MOS Sleep Scale, at Week 12 Using LOCF | 0.6 hours | Standard Deviation 1.25 |
| GEn (XP13512/GSK1838262) 1200 mg | Change From Baseline in Sleep Quantity, an Item on the MOS Sleep Scale, at Week 12 Using LOCF | 0.8 hours | Standard Deviation 1.66 |
Secondary
Change From Baseline in the Average Daily RLS Pain Score at the End of Treatment (Week 12) for Participants With Pain at Baseline or the End of Week 12 Using LOCF
The Daily RLS pain score was assessed by participants reporting whether they experienced any pain associated with RLS in the last 24 hours and rating their pain levels on an 11-point numerical rating scale, with 0 being no pain and 10 the most intense pain imaginable. The assessment was performed for 7 days prior to Baseline and pre-defined study visits. The change from baseline was calculated as the End of Treatment (Week 12) value minus the Baseline (Day 1) value.
Time frame: Baseline and End of Treatment (Week 12)
Population: MITT Population. The number of participants assessed varies due to incomplete/missing data.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline in the Average Daily RLS Pain Score at the End of Treatment (Week 12) for Participants With Pain at Baseline or the End of Week 12 Using LOCF | -1.7 scores on a scale | Standard Deviation 2.28 |
| GEn (XP13512/GSK1838262) 1200 mg | Change From Baseline in the Average Daily RLS Pain Score at the End of Treatment (Week 12) for Participants With Pain at Baseline or the End of Week 12 Using LOCF | -2.5 scores on a scale | Standard Deviation 2.2 |
| GEn (XP13512/GSK1838262) 1200 mg | Change From Baseline in the Average Daily RLS Pain Score at the End of Treatment (Week 12) for Participants With Pain at Baseline or the End of Week 12 Using LOCF | -2.6 scores on a scale | Standard Deviation 2.43 |
Secondary
Change From Baseline in the Average Daily RLS Pain Score to Week 12 for Participants With a Baseline Pain Score of at Least 4 Using LOCF
The Average Daily RLS pain was assessed by participants reporting whether they experienced any pain associated with RLS in the last 24 hours and rating their pain levels on an 11-point numerical rating scale, with 0 being no pain and 10 the most intense pain imaginable. The assessment was performed for 7 days prior to Baseline and pre-defined visits. The change from baseline was calculated as the End of Treatment (Week 12) value minus the Baseline (Day 1) value.
Time frame: Baseline and Week 12
Population: MITT Population. The number of participants assessed varies due to incomplete/missing data.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline in the Average Daily RLS Pain Score to Week 12 for Participants With a Baseline Pain Score of at Least 4 Using LOCF | -2.3 scores on a scale | Standard Deviation 2.34 |
| GEn (XP13512/GSK1838262) 1200 mg | Change From Baseline in the Average Daily RLS Pain Score to Week 12 for Participants With a Baseline Pain Score of at Least 4 Using LOCF | -3.5 scores on a scale | Standard Deviation 2.19 |
| GEn (XP13512/GSK1838262) 1200 mg | Change From Baseline in the Average Daily RLS Pain Score to Week 12 for Participants With a Baseline Pain Score of at Least 4 Using LOCF | -3.5 scores on a scale | Standard Deviation 2.51 |
Secondary
Change From Baseline in the Daytime Somnolence Score, an Item on the Medical Outcomes Study (MOS) Sleep Scale, at Week 12 Using LOCF
The MOS Sleep Scale measures most constructs of sleep. The scale has a battery of questions to measure specific aspects of sleep in participants with co-morbidities. The four domains scored from the MOS Sleep Scale were sleep disturbance,' sleep quantity,' sleep adequacy, and daytime somnolence. The scores of the daytime somnolence domain ranged from 1 to 100, with a high score indicating greater daytime somnolence. The assessment was completed at Baseline (Day 1) and end of Weeks, 4, 8, and 12 (or end of Treatment).
Time frame: Baseline and Week 12
Population: MITT Population. The number of participants assessed varies due to incomplete/missing data.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline in the Daytime Somnolence Score, an Item on the Medical Outcomes Study (MOS) Sleep Scale, at Week 12 Using LOCF | -9.7 scores on a scale | Standard Deviation 20.39 |
| GEn (XP13512/GSK1838262) 1200 mg | Change From Baseline in the Daytime Somnolence Score, an Item on the Medical Outcomes Study (MOS) Sleep Scale, at Week 12 Using LOCF | -9.8 scores on a scale | Standard Deviation 20.35 |
| GEn (XP13512/GSK1838262) 1200 mg | Change From Baseline in the Daytime Somnolence Score, an Item on the Medical Outcomes Study (MOS) Sleep Scale, at Week 12 Using LOCF | -16.1 scores on a scale | Standard Deviation 19.58 |
Secondary
Change From Baseline in the IRLS Rating Scale Total Score at Week 12 by Baseline RLS Rating Scale Total Score Category (Baseline RLS Severity) Using LOCF
The IRLS Rating scale is a measure of RLS disease severity. The scale reflects the participant-reported assessment of primary sensory and motor features and associated sleep problems in RLS. Ten items (individually scored from 0 to 4) are included that assess the impact of symptoms on participants' mood, daily life, and activities. The total scale score is a sum of all of the individual item scores and ranges from 0-40 points, with 40 being the most severe. The scale assesses symptoms over the week prior to measurement.
Time frame: Baseline (Day 1) and Week 12
Population: MITT Population. The number of participants assessed varies due to incomplete/missing data.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Change From Baseline in the IRLS Rating Scale Total Score at Week 12 by Baseline RLS Rating Scale Total Score Category (Baseline RLS Severity) Using LOCF | IRLS Total Score < 17.5 | -6.3 scores on a scale | Standard Deviation 4.98 |
| Placebo | Change From Baseline in the IRLS Rating Scale Total Score at Week 12 by Baseline RLS Rating Scale Total Score Category (Baseline RLS Severity) Using LOCF | IRLS Total Score 17.5 to < 22.5 | -8.5 scores on a scale | Standard Deviation 7.11 |
| Placebo | Change From Baseline in the IRLS Rating Scale Total Score at Week 12 by Baseline RLS Rating Scale Total Score Category (Baseline RLS Severity) Using LOCF | IRLS Total Score 22.5 to < 27.5 | -9.6 scores on a scale | Standard Deviation 8.21 |
| Placebo | Change From Baseline in the IRLS Rating Scale Total Score at Week 12 by Baseline RLS Rating Scale Total Score Category (Baseline RLS Severity) Using LOCF | IRLS Total Score >= 27.5 | -13.3 scores on a scale | Standard Deviation 7.74 |
| GEn (XP13512/GSK1838262) 1200 mg | Change From Baseline in the IRLS Rating Scale Total Score at Week 12 by Baseline RLS Rating Scale Total Score Category (Baseline RLS Severity) Using LOCF | IRLS Total Score >= 27.5 | -18.2 scores on a scale | Standard Deviation 11.28 |
| GEn (XP13512/GSK1838262) 1200 mg | Change From Baseline in the IRLS Rating Scale Total Score at Week 12 by Baseline RLS Rating Scale Total Score Category (Baseline RLS Severity) Using LOCF | IRLS Total Score < 17.5 | -8.9 scores on a scale | Standard Deviation 6.02 |
| GEn (XP13512/GSK1838262) 1200 mg | Change From Baseline in the IRLS Rating Scale Total Score at Week 12 by Baseline RLS Rating Scale Total Score Category (Baseline RLS Severity) Using LOCF | IRLS Total Score 22.5 to < 27.5 | -15.1 scores on a scale | Standard Deviation 6.65 |
| GEn (XP13512/GSK1838262) 1200 mg | Change From Baseline in the IRLS Rating Scale Total Score at Week 12 by Baseline RLS Rating Scale Total Score Category (Baseline RLS Severity) Using LOCF | IRLS Total Score 17.5 to < 22.5 | -11.9 scores on a scale | Standard Deviation 6.34 |
| GEn (XP13512/GSK1838262) 1200 mg | Change From Baseline in the IRLS Rating Scale Total Score at Week 12 by Baseline RLS Rating Scale Total Score Category (Baseline RLS Severity) Using LOCF | IRLS Total Score >= 27.5 | -19.6 scores on a scale | Standard Deviation 8.8 |
| GEn (XP13512/GSK1838262) 1200 mg | Change From Baseline in the IRLS Rating Scale Total Score at Week 12 by Baseline RLS Rating Scale Total Score Category (Baseline RLS Severity) Using LOCF | IRLS Total Score 17.5 to < 22.5 | -8.8 scores on a scale | Standard Deviation 7.77 |
| GEn (XP13512/GSK1838262) 1200 mg | Change From Baseline in the IRLS Rating Scale Total Score at Week 12 by Baseline RLS Rating Scale Total Score Category (Baseline RLS Severity) Using LOCF | IRLS Total Score 22.5 to < 27.5 | -15.5 scores on a scale | Standard Deviation 8.12 |
| GEn (XP13512/GSK1838262) 1200 mg | Change From Baseline in the IRLS Rating Scale Total Score at Week 12 by Baseline RLS Rating Scale Total Score Category (Baseline RLS Severity) Using LOCF | IRLS Total Score < 17.5 | -7.9 scores on a scale | Standard Deviation 6.81 |
Secondary
Change From Baseline in the Overall Life-Impact Score of the RLS Quality of Life (QoL) Questionnaire at Week 12 Using LOCF
The Restless Legs Syndrome Quality of Life (RLS-QoL) questionnaire is a disease-specific, participant-rated questionnaire that assesses the impact of RLS on daily life, emotional well-being, social life, and work life of the participants. The RLS-QoL Questionnaire is presented on a 0 (lowest possible score) to 100 (highest possible score) scale. It was completed at Day 1 and at the end of Weeks 4, 8, and 12 (or Early Termination).
Time frame: Baseline and Week 12
Population: MITT Population: The number of participants assessed varies due to incomplete/missing data.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline in the Overall Life-Impact Score of the RLS Quality of Life (QoL) Questionnaire at Week 12 Using LOCF | 14.5 scores on a scale | Standard Deviation 15.74 |
| GEn (XP13512/GSK1838262) 1200 mg | Change From Baseline in the Overall Life-Impact Score of the RLS Quality of Life (QoL) Questionnaire at Week 12 Using LOCF | 19.3 scores on a scale | Standard Deviation 15.57 |
| GEn (XP13512/GSK1838262) 1200 mg | Change From Baseline in the Overall Life-Impact Score of the RLS Quality of Life (QoL) Questionnaire at Week 12 Using LOCF | 20.4 scores on a scale | Standard Deviation 17.14 |
Secondary
Change From Baseline in the Profile of Mood State (POMS) Scale at Week 12 Using LOCF
The Profile of Mood States (POMS) Brief Form contains 30 adjectives; each participant is asked to rate the degree to which each adjective describes themselves based on how they felt during the past week including the date on which the adjective was rated. The possible ratings range from 0 (Not all all) to 4 (Extremely). The Total Mood Disturbance Score (range of 0 to 120) is obtained by summing the values of six domains. Higher scores indicate a more negative mood disturbance. The POMS was completed at Baseline (Day 1), and at the end of Weeks 4, 8, and 12 (or Early Termination).
Time frame: Baseline to End of Treatment (Week 12)
Population: MITT Population. The number of participants assessed varies due to incomplete/missing data.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline in the Profile of Mood State (POMS) Scale at Week 12 Using LOCF | -7.3 scores on a scale | Standard Deviation 14.89 |
| GEn (XP13512/GSK1838262) 1200 mg | Change From Baseline in the Profile of Mood State (POMS) Scale at Week 12 Using LOCF | -10.9 scores on a scale | Standard Deviation 17.97 |
| GEn (XP13512/GSK1838262) 1200 mg | Change From Baseline in the Profile of Mood State (POMS) Scale at Week 12 Using LOCF | -11.5 scores on a scale | Standard Deviation 16.87 |
Secondary
Change From Baseline in the Sleep Disturbance Score, an Item on the MOS Sleep Scale, at Week 12 Using LOCF
The MOS Sleep Scale measures most constructs of sleep. The scale has a battery of questions to measure specific aspects of sleep in participants with co-morbidities. The four domains scored from the MOS Sleep Scale were sleep disturbance,' sleep quantity,' sleep adequacy, and daytime somnolence. The scores of the sleep disturbance domain ranged from 1 to 100, with a high score indicating greater impairment of sleep. The assessment was completed at Baseline (Day 1) and end of Weeks, 4, 8, and 12 (or end of Treatment).
Time frame: Baseline and Week 12
Population: MITT Population. The number of participants assessed varies due to incomplete/missing data.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline in the Sleep Disturbance Score, an Item on the MOS Sleep Scale, at Week 12 Using LOCF | -17.0 scores on a scale | Standard Deviation 20.4 |
| GEn (XP13512/GSK1838262) 1200 mg | Change From Baseline in the Sleep Disturbance Score, an Item on the MOS Sleep Scale, at Week 12 Using LOCF | -29.5 scores on a scale | Standard Deviation 23.27 |
| GEn (XP13512/GSK1838262) 1200 mg | Change From Baseline in the Sleep Disturbance Score, an Item on the MOS Sleep Scale, at Week 12 Using LOCF | -30.7 scores on a scale | Standard Deviation 25.45 |
Secondary
Change From Baseline to the End of Treatment in Average Daily Total Sleep Time (Hours) Using LOCF
Average daily total sleep time was derived from the Pittsburgh Sleep Diary (PghSD; an instrument with separate components to be completed \[self-reported\] at bedtime and waketime) as the mean of non-missing total sleep time over the 7 days before each visit, where total sleep time = \[(wake up time - lights out time) - time to fall asleep - time awake during the night\] in hours. The change was calculated as the end of treatment (Week 12) value minus the Baseline value.
Time frame: Baseline to End of Treatment (Week 12)
Population: MITT Population. The number of participants assessed varies due to incomplete/missing data.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline to the End of Treatment in Average Daily Total Sleep Time (Hours) Using LOCF | 0.6 hours | Standard Deviation 1.36 |
| GEn (XP13512/GSK1838262) 1200 mg | Change From Baseline to the End of Treatment in Average Daily Total Sleep Time (Hours) Using LOCF | 0.7 hours | Standard Deviation 1.25 |
| GEn (XP13512/GSK1838262) 1200 mg | Change From Baseline to the End of Treatment in Average Daily Total Sleep Time (Hours) Using LOCF | 1.0 hours | Standard Deviation 1.32 |
Secondary
Change From Baseline to the End of Treatment in Average Daily Wake Time (Minutes) After Sleep Onset Using LOCF
Average daily wake time after sleep onset was derived from the Pittsburgh Sleep Diary (PghSD) as the mean of non-missing total hours awake during the night after falling asleep over the 7 days before each visit. The change was calculated as the end of treatment (Week 12) value minus the Baseline value.
Time frame: Baseline to End of Treatment (Week 12)
Population: MITT Popultion. The number of participants assessed varies due to incomplete/missing data.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline to the End of Treatment in Average Daily Wake Time (Minutes) After Sleep Onset Using LOCF | -12.5 minutes | Standard Deviation 31.01 |
| GEn (XP13512/GSK1838262) 1200 mg | Change From Baseline to the End of Treatment in Average Daily Wake Time (Minutes) After Sleep Onset Using LOCF | -16.4 minutes | Standard Deviation 22.33 |
| GEn (XP13512/GSK1838262) 1200 mg | Change From Baseline to the End of Treatment in Average Daily Wake Time (Minutes) After Sleep Onset Using LOCF | -18.5 minutes | Standard Deviation 28.67 |
Secondary
Change From Baseline to the End of Treatment (Week 12) in the IRLS Rating Scale Total Score Using LOCF
The IRLS Rating scale is a measure of RLS disease severity. The scale reflects the participant-reported assessment of primary sensory and motor features and associated sleep problems in RLS. Items (individually scored from 0 to 4) are included that assess the impact of symptoms on participants' mood, daily life, and activities. The total scale score is a sum of all of the individual item scores and ranges from 0-40 points, with 40 being the most severe. The scale assesses symptoms over the week prior to measurement.
Time frame: Baseline (Day 1) and End of Treatment (Week 12)
Population: MITT Population. The number of participants assessed varies due to incomplete/missing data.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline to the End of Treatment (Week 12) in the IRLS Rating Scale Total Score Using LOCF | -9.8 scores on a scale | Standard Deviation 7.69 |
| GEn (XP13512/GSK1838262) 1200 mg | Change From Baseline to the End of Treatment (Week 12) in the IRLS Rating Scale Total Score Using LOCF | -13.8 scores on a scale | Standard Deviation 8.09 |
Secondary
Change From Baseline to the End of Week 1 in the IRLS Rating Scale Total Score Using LOCF
The IRLS Rating scale is a measure of RLS disease severity. The scale reflects the participant-reported assessment of primary sensory and motor features and associated sleep problems in RLS. Items (individually scored from 0 to 4) are included that assess the impact of symptoms on participants' mood, daily life, and activities. The total scale score is a sum of all of the individual item scores and ranges from 0-40 points, with 40 being the most severe. The scale assesses symptoms over the week prior to measurement.
Time frame: Baseline and the End of Week 1
Population: MITT Population. The number of participants assessed varies due to incomplete/missing data.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline to the End of Week 1 in the IRLS Rating Scale Total Score Using LOCF | -6.0 scores on a scale | Standard Deviation 5.59 |
| GEn (XP13512/GSK1838262) 1200 mg | Change From Baseline to the End of Week 1 in the IRLS Rating Scale Total Score Using LOCF | -9.8 scores on a scale | Standard Deviation 7.76 |
| GEn (XP13512/GSK1838262) 1200 mg | Change From Baseline to the End of Week 1 in the IRLS Rating Scale Total Score Using LOCF | -8.7 scores on a scale | Standard Deviation 8.09 |
Secondary
Mean Change in the IRLS Rating Scale Total Score From Baseline at Week 12 by RLS Treatment History Using LOCF
The IRLS Rating scale is a measure of RLS disease severity. The scale reflects the participant-reported assessment of primary sensory and motor features and associated sleep problems in RLS. Ten items (individually scored from 0 to 4) are included that assess the impact of symptoms on participants' mood, daily life, and activities. The total scale score is a sum of all of the individual item scores and ranges from 0-40 points, with 40 being the most severe. The scale assesses symptoms over the week prior to measurement.
Time frame: Baseline (Day 1) and Week 12
Population: MITT Population. The number of participants assessed varies due to incomplete/missing data.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Mean Change in the IRLS Rating Scale Total Score From Baseline at Week 12 by RLS Treatment History Using LOCF | Treatment terminated | -13.3 scores on a scale | Standard Deviation 9.09 |
| Placebo | Mean Change in the IRLS Rating Scale Total Score From Baseline at Week 12 by RLS Treatment History Using LOCF | No RLS Treatment History | -8.8 scores on a scale | Standard Deviation 7.08 |
| Placebo | Mean Change in the IRLS Rating Scale Total Score From Baseline at Week 12 by RLS Treatment History Using LOCF | Treatment within 1 month of study start | -10.7 scores on a scale | Standard Deviation 8.11 |
| GEn (XP13512/GSK1838262) 1200 mg | Mean Change in the IRLS Rating Scale Total Score From Baseline at Week 12 by RLS Treatment History Using LOCF | Treatment terminated | -12.4 scores on a scale | Standard Deviation 7.26 |
| GEn (XP13512/GSK1838262) 1200 mg | Mean Change in the IRLS Rating Scale Total Score From Baseline at Week 12 by RLS Treatment History Using LOCF | No RLS Treatment History | -13.7 scores on a scale | Standard Deviation 8.23 |
| GEn (XP13512/GSK1838262) 1200 mg | Mean Change in the IRLS Rating Scale Total Score From Baseline at Week 12 by RLS Treatment History Using LOCF | Treatment within 1 month of study start | -14.6 scores on a scale | Standard Deviation 8.39 |
| GEn (XP13512/GSK1838262) 1200 mg | Mean Change in the IRLS Rating Scale Total Score From Baseline at Week 12 by RLS Treatment History Using LOCF | No RLS Treatment History | -12.5 scores on a scale | Standard Deviation 8.78 |
| GEn (XP13512/GSK1838262) 1200 mg | Mean Change in the IRLS Rating Scale Total Score From Baseline at Week 12 by RLS Treatment History Using LOCF | Treatment within 1 month of study start | -12.1 scores on a scale | Standard Deviation 10.43 |
| GEn (XP13512/GSK1838262) 1200 mg | Mean Change in the IRLS Rating Scale Total Score From Baseline at Week 12 by RLS Treatment History Using LOCF | Treatment terminated | -17.1 scores on a scale | Standard Deviation 7.94 |
Secondary
Number of Participants Classified as Investigator-rated CGI-I Scale Responders at Week 12 by RLS Treatment History Using LOCF
The CGI-I scale is a standardized tool that is widely used in psychopharmacologic trials. For the CGI-I, the investigator was asked to rate the participant's overall change in RLS symptoms from Baseline. Scores ranged from 1 (very much improved) to 7 (very much worse). Participants who were much improved (score of 2) or very much improved on the CGI-I scale at the end of treatment (Week 12) are classified as Responders.
Time frame: Basline and Week 12
Population: Participants included in the MITT Population with a known RLS treatment history
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Placebo | Number of Participants Classified as Investigator-rated CGI-I Scale Responders at Week 12 by RLS Treatment History Using LOCF | Treatment terminated | 5 participants |
| Placebo | Number of Participants Classified as Investigator-rated CGI-I Scale Responders at Week 12 by RLS Treatment History Using LOCF | No RLS Treatment History | 26 participants |
| Placebo | Number of Participants Classified as Investigator-rated CGI-I Scale Responders at Week 12 by RLS Treatment History Using LOCF | Treatment within 1 month of study start | 11 participants |
| GEn (XP13512/GSK1838262) 1200 mg | Number of Participants Classified as Investigator-rated CGI-I Scale Responders at Week 12 by RLS Treatment History Using LOCF | Treatment terminated | 9 participants |
| GEn (XP13512/GSK1838262) 1200 mg | Number of Participants Classified as Investigator-rated CGI-I Scale Responders at Week 12 by RLS Treatment History Using LOCF | No RLS Treatment History | 54 participants |
| GEn (XP13512/GSK1838262) 1200 mg | Number of Participants Classified as Investigator-rated CGI-I Scale Responders at Week 12 by RLS Treatment History Using LOCF | Treatment within 1 month of study start | 18 participants |
| GEn (XP13512/GSK1838262) 1200 mg | Number of Participants Classified as Investigator-rated CGI-I Scale Responders at Week 12 by RLS Treatment History Using LOCF | No RLS Treatment History | 57 participants |
| GEn (XP13512/GSK1838262) 1200 mg | Number of Participants Classified as Investigator-rated CGI-I Scale Responders at Week 12 by RLS Treatment History Using LOCF | Treatment within 1 month of study start | 15 participants |
| GEn (XP13512/GSK1838262) 1200 mg | Number of Participants Classified as Investigator-rated CGI-I Scale Responders at Week 12 by RLS Treatment History Using LOCF | Treatment terminated | 13 participants |
Secondary
Number of Participants Classified as Responders to Treatment Based on the Participant-Rated CGI of Improvement at Week 1 and Week 12 (End of Treatment)
The CGI-I scale is a standardized tool that is widely used in psychopharmacologic trials. For the CGI-I, the investigator was asked to rate the participant's overall change in RLS symptoms from Baseline. Scores ranged from 1 (very much improved) to 7 (very much worse). Participants who were much improved (score of 2) or very much improved on the CGI-I scale at the end of treatment (Week 12) are classified as Responders.
Time frame: Week 1 and Week 12
Population: MITT Population. The number of participants assessed varies due to incomplete/missing data.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Placebo | Number of Participants Classified as Responders to Treatment Based on the Participant-Rated CGI of Improvement at Week 1 and Week 12 (End of Treatment) | Responders at the End of Treatment (Week 12) | 46 participants |
| Placebo | Number of Participants Classified as Responders to Treatment Based on the Participant-Rated CGI of Improvement at Week 1 and Week 12 (End of Treatment) | Responders at the End of One Week | 20 participants |
| GEn (XP13512/GSK1838262) 1200 mg | Number of Participants Classified as Responders to Treatment Based on the Participant-Rated CGI of Improvement at Week 1 and Week 12 (End of Treatment) | Responders at the End of Treatment (Week 12) | 90 participants |
| GEn (XP13512/GSK1838262) 1200 mg | Number of Participants Classified as Responders to Treatment Based on the Participant-Rated CGI of Improvement at Week 1 and Week 12 (End of Treatment) | Responders at the End of One Week | 55 participants |
| GEn (XP13512/GSK1838262) 1200 mg | Number of Participants Classified as Responders to Treatment Based on the Participant-Rated CGI of Improvement at Week 1 and Week 12 (End of Treatment) | Responders at the End of Treatment (Week 12) | 83 participants |
| GEn (XP13512/GSK1838262) 1200 mg | Number of Participants Classified as Responders to Treatment Based on the Participant-Rated CGI of Improvement at Week 1 and Week 12 (End of Treatment) | Responders at the End of One Week | 52 participants |
Secondary
Number of Participants Classified as Responders With at Least 30% and 50% Improvement in the Average Daily RLS Pain Score Using LOCF
The Mean Daily RLS pain was assessed by participants reporting whether they experienced any pain associated with RLS in the last 24 hours and rating their pain levels on an 11-point numerical rating scale, with 0 being no pain and 10 the most intense pain imaginable. The assessment was performed for 7 days prior to Baseline and pre-defined visits A Responder is a participant with a score of much improved or very much improved on the investigator rated CGI I Scale at the end of treatment (Week 12 using LOCF).
Time frame: Week 12
Population: MITT Population. The number of participants assessed varies due to incomplete/missing data.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Placebo | Number of Participants Classified as Responders With at Least 30% and 50% Improvement in the Average Daily RLS Pain Score Using LOCF | > or equal to 30% response | 48 participants |
| Placebo | Number of Participants Classified as Responders With at Least 30% and 50% Improvement in the Average Daily RLS Pain Score Using LOCF | > or equal to 50% response | 41 participants |
| GEn (XP13512/GSK1838262) 1200 mg | Number of Participants Classified as Responders With at Least 30% and 50% Improvement in the Average Daily RLS Pain Score Using LOCF | > or equal to 30% response | 75 participants |
| GEn (XP13512/GSK1838262) 1200 mg | Number of Participants Classified as Responders With at Least 30% and 50% Improvement in the Average Daily RLS Pain Score Using LOCF | > or equal to 50% response | 62 participants |
| GEn (XP13512/GSK1838262) 1200 mg | Number of Participants Classified as Responders With at Least 30% and 50% Improvement in the Average Daily RLS Pain Score Using LOCF | > or equal to 30% response | 76 participants |
| GEn (XP13512/GSK1838262) 1200 mg | Number of Participants Classified as Responders With at Least 30% and 50% Improvement in the Average Daily RLS Pain Score Using LOCF | > or equal to 50% response | 66 participants |
Secondary
Number of Participants Classsified as Responders on the Investigator-rated CGI-I Scale at Week 12 Using LOCF
The CGI-I scale is a standardized tool that is widely used in psychopharmacologic trials. For the CGI-I, the investigator was asked to rate the participant's overall change in RLS symptoms from Baseline. Scores ranged from 1 (very much improved) to 7 (very much worse). Participants who were much improved (score of 2) or very much improved on the CGI-I scale at the end of treatment (Week 12) are classified as Responders.
Time frame: Week 12
Population: MITT Population. The number of participants assessed varies due to incomplete/missing data.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Placebo | Number of Participants Classsified as Responders on the Investigator-rated CGI-I Scale at Week 12 Using LOCF | 43 participants |
| GEn (XP13512/GSK1838262) 1200 mg | Number of Participants Classsified as Responders on the Investigator-rated CGI-I Scale at Week 12 Using LOCF | 83 participants |
Secondary
Number of Participants Experiencing No RLS Symptoms in Each of the Seven 4-hour Periods From the 24-hour RLS Record at Week 12 (End of Treatment)
RLS severity ratings were summarized in 6 non-overlapping 4-hour periods beginning at 8 AM. A 4-hour period from 6 PM to 10 PM was also prospectively included to reflect the time frame when the most participants would experience their first symptoms of the day.
Time frame: Week 12
Population: MITT Population. The number analyzed represents participants within the MITT Population who reported no RLS symptoms at the end of Week 12.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Placebo | Number of Participants Experiencing No RLS Symptoms in Each of the Seven 4-hour Periods From the 24-hour RLS Record at Week 12 (End of Treatment) | 12 PM to 4 PM | 51 participants |
| Placebo | Number of Participants Experiencing No RLS Symptoms in Each of the Seven 4-hour Periods From the 24-hour RLS Record at Week 12 (End of Treatment) | 8 PM to 12 AM | 27 participants |
| Placebo | Number of Participants Experiencing No RLS Symptoms in Each of the Seven 4-hour Periods From the 24-hour RLS Record at Week 12 (End of Treatment) | 6 PM to 10 PM | 39 participants |
| Placebo | Number of Participants Experiencing No RLS Symptoms in Each of the Seven 4-hour Periods From the 24-hour RLS Record at Week 12 (End of Treatment) | 8 AM to 12 PM | 52 participants |
| Placebo | Number of Participants Experiencing No RLS Symptoms in Each of the Seven 4-hour Periods From the 24-hour RLS Record at Week 12 (End of Treatment) | 4 AM to 8 AM | 56 participants |
| Placebo | Number of Participants Experiencing No RLS Symptoms in Each of the Seven 4-hour Periods From the 24-hour RLS Record at Week 12 (End of Treatment) | 12 AM to 4 AM | 38 participants |
| Placebo | Number of Participants Experiencing No RLS Symptoms in Each of the Seven 4-hour Periods From the 24-hour RLS Record at Week 12 (End of Treatment) | 4 PM to 8 PM | 45 participants |
| GEn (XP13512/GSK1838262) 1200 mg | Number of Participants Experiencing No RLS Symptoms in Each of the Seven 4-hour Periods From the 24-hour RLS Record at Week 12 (End of Treatment) | 6 PM to 10 PM | 55 participants |
| GEn (XP13512/GSK1838262) 1200 mg | Number of Participants Experiencing No RLS Symptoms in Each of the Seven 4-hour Periods From the 24-hour RLS Record at Week 12 (End of Treatment) | 8 AM to 12 PM | 85 participants |
| GEn (XP13512/GSK1838262) 1200 mg | Number of Participants Experiencing No RLS Symptoms in Each of the Seven 4-hour Periods From the 24-hour RLS Record at Week 12 (End of Treatment) | 12 PM to 4 PM | 74 participants |
| GEn (XP13512/GSK1838262) 1200 mg | Number of Participants Experiencing No RLS Symptoms in Each of the Seven 4-hour Periods From the 24-hour RLS Record at Week 12 (End of Treatment) | 4 PM to 8 PM | 68 participants |
| GEn (XP13512/GSK1838262) 1200 mg | Number of Participants Experiencing No RLS Symptoms in Each of the Seven 4-hour Periods From the 24-hour RLS Record at Week 12 (End of Treatment) | 8 PM to 12 AM | 49 participants |
| GEn (XP13512/GSK1838262) 1200 mg | Number of Participants Experiencing No RLS Symptoms in Each of the Seven 4-hour Periods From the 24-hour RLS Record at Week 12 (End of Treatment) | 12 AM to 4 AM | 74 participants |
| GEn (XP13512/GSK1838262) 1200 mg | Number of Participants Experiencing No RLS Symptoms in Each of the Seven 4-hour Periods From the 24-hour RLS Record at Week 12 (End of Treatment) | 4 AM to 8 AM | 79 participants |
| GEn (XP13512/GSK1838262) 1200 mg | Number of Participants Experiencing No RLS Symptoms in Each of the Seven 4-hour Periods From the 24-hour RLS Record at Week 12 (End of Treatment) | 8 PM to 12 AM | 48 participants |
| GEn (XP13512/GSK1838262) 1200 mg | Number of Participants Experiencing No RLS Symptoms in Each of the Seven 4-hour Periods From the 24-hour RLS Record at Week 12 (End of Treatment) | 12 PM to 4 PM | 69 participants |
| GEn (XP13512/GSK1838262) 1200 mg | Number of Participants Experiencing No RLS Symptoms in Each of the Seven 4-hour Periods From the 24-hour RLS Record at Week 12 (End of Treatment) | 4 AM to 8 AM | 72 participants |
| GEn (XP13512/GSK1838262) 1200 mg | Number of Participants Experiencing No RLS Symptoms in Each of the Seven 4-hour Periods From the 24-hour RLS Record at Week 12 (End of Treatment) | 12 AM to 4 AM | 67 participants |
| GEn (XP13512/GSK1838262) 1200 mg | Number of Participants Experiencing No RLS Symptoms in Each of the Seven 4-hour Periods From the 24-hour RLS Record at Week 12 (End of Treatment) | 6 PM to 10 PM | 55 participants |
| GEn (XP13512/GSK1838262) 1200 mg | Number of Participants Experiencing No RLS Symptoms in Each of the Seven 4-hour Periods From the 24-hour RLS Record at Week 12 (End of Treatment) | 4 PM to 8 PM | 61 participants |
| GEn (XP13512/GSK1838262) 1200 mg | Number of Participants Experiencing No RLS Symptoms in Each of the Seven 4-hour Periods From the 24-hour RLS Record at Week 12 (End of Treatment) | 8 AM to 12 PM | 74 participants |
Secondary
Number of Participants Who Had an Onset of Response to Treatment at the End of Week 1 Based Upon the IRLS Rating Scale Total Score and the Investigator-rated CGI-I Using LOCF
The IRLS Rating scale is a measure of RLS disease severity. Items (individually scored from 0 to 4) are included that assess the impact of symptoms on participants' mood, daily life, and activities. The total scale score is a sum of all of the individual item scores and ranges from 0-40 points, with 40 being the most severe. Response was defined by an IRLS Rating Scale total score at the end of Week 1 \< 15 and at least a 6-point reduction from the participant's Baseline score and an investigator-rated CGI-I response of much improved or very much improved.
Time frame: End of Week 1
Population: MITT Population. The number of participants assessed varies due to incomplete/missing data.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Placebo | Number of Participants Who Had an Onset of Response to Treatment at the End of Week 1 Based Upon the IRLS Rating Scale Total Score and the Investigator-rated CGI-I Using LOCF | 13 participants |
| GEn (XP13512/GSK1838262) 1200 mg | Number of Participants Who Had an Onset of Response to Treatment at the End of Week 1 Based Upon the IRLS Rating Scale Total Score and the Investigator-rated CGI-I Using LOCF | 36 participants |
| GEn (XP13512/GSK1838262) 1200 mg | Number of Participants Who Had an Onset of Response to Treatment at the End of Week 1 Based Upon the IRLS Rating Scale Total Score and the Investigator-rated CGI-I Using LOCF | 40 participants |
Secondary
Number of Participants Who Indicated on the Mood Assessment That Their Mood Was Much Improved or Very Much Improved at Week 12 (End of Treatment) Using LOCF
The Mood Assessment is a non-disease-specific question surveying global change in a participant's overall mood. Participants were asked to rate their overall change in mood since the start of the study by choosing a score in a range from 1 (Very Much Improved) to 7 (Very Much Worse). The assessment was completed at Day 1 and the ends of Weeks 4, 8, and 12 or (Early Termination).
Time frame: Week 12
Population: MITT Population. The number of participants assessed varies due to incomplete/missing data.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Placebo | Number of Participants Who Indicated on the Mood Assessment That Their Mood Was Much Improved or Very Much Improved at Week 12 (End of Treatment) Using LOCF | 19 participants |
| GEn (XP13512/GSK1838262) 1200 mg | Number of Participants Who Indicated on the Mood Assessment That Their Mood Was Much Improved or Very Much Improved at Week 12 (End of Treatment) Using LOCF | 35 participants |
| GEn (XP13512/GSK1838262) 1200 mg | Number of Participants Who Indicated on the Mood Assessment That Their Mood Was Much Improved or Very Much Improved at Week 12 (End of Treatment) Using LOCF | 39 participants |
Secondary
Number of Participants With a Rating of Excellent for the Overall Quality of Sleep in Past Week Measured by the Post-Sleep Questionnaire (PSQ) at the End of Treatment (Week 12) Using LOCF
The Post-Sleep Questionnaire (PSQ) was designed to evaluate overall sleep quality, ability to function, and RLS symptoms' interference with sleep over the past week. Participants were asked to rate overall sleep quality (as either Excellent, Reasonable, or Poor), ability to function, number of nights with RLS symptoms, number of nights awakened by RLS symptoms, and the number of hours spent awake due to RLS symptoms over the past week.
Time frame: End of Treatment (Week 12)
Population: MITT Population. The number of participants assessed varies due to incomplete/missing data.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Placebo | Number of Participants With a Rating of Excellent for the Overall Quality of Sleep in Past Week Measured by the Post-Sleep Questionnaire (PSQ) at the End of Treatment (Week 12) Using LOCF | 14 participants |
| GEn (XP13512/GSK1838262) 1200 mg | Number of Participants With a Rating of Excellent for the Overall Quality of Sleep in Past Week Measured by the Post-Sleep Questionnaire (PSQ) at the End of Treatment (Week 12) Using LOCF | 24 participants |
| GEn (XP13512/GSK1838262) 1200 mg | Number of Participants With a Rating of Excellent for the Overall Quality of Sleep in Past Week Measured by the Post-Sleep Questionnaire (PSQ) at the End of Treatment (Week 12) Using LOCF | 30 participants |
Secondary
Number of Total Responders to Treatment Based on the Investigator-Rated CGI of Improvement at the End of One Week of Treatment
The CGI-I scale is a standardized tool that is widely used in psychopharmacologic trials. For the CGI-I, the investigator was asked to rate the participant's overall change in RLS symptoms from Baseline. Scores ranged from 1 (very much improved) to 7 (very much worse). Participants who were much improved (score of 2) or very much improved on the CGI-I scale at the end of treatment (Week 12) are classified as Responders.
Time frame: End of Week 1
Population: MITT Population. The number of participants assessed varies due to incomplete/missing data.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Placebo | Number of Total Responders to Treatment Based on the Investigator-Rated CGI of Improvement at the End of One Week of Treatment | 26 responders |
| GEn (XP13512/GSK1838262) 1200 mg | Number of Total Responders to Treatment Based on the Investigator-Rated CGI of Improvement at the End of One Week of Treatment | 54 responders |
| GEn (XP13512/GSK1838262) 1200 mg | Number of Total Responders to Treatment Based on the Investigator-Rated CGI of Improvement at the End of One Week of Treatment | 59 responders |
Secondary
The Time to Onset of the First Response to Treatment on the IRLS Rating Scale Total Score and the Investigator-rated CGI-I
The Response was defined by an IRLS Rating Scale total score at the end of Week 1 \< 15 and at least a 6-point reduction from the participant's Baseline score and an investigator-rated CGI-I response of much improved or very much improved. The median time to onset is estimated using the product-limit estimation method.
Time frame: Baseline (Day 1) to End of Treatment (Week 12)
Population: MITT Population. The number of participants assessed varies due to incomplete/missing data.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Placebo | The Time to Onset of the First Response to Treatment on the IRLS Rating Scale Total Score and the Investigator-rated CGI-I | NA weeks |
| GEn (XP13512/GSK1838262) 1200 mg | The Time to Onset of the First Response to Treatment on the IRLS Rating Scale Total Score and the Investigator-rated CGI-I | 4.1 weeks |
| GEn (XP13512/GSK1838262) 1200 mg | The Time to Onset of the First Response to Treatment on the IRLS Rating Scale Total Score and the Investigator-rated CGI-I | 2.1 weeks |
Secondary
Time to Onset of the First RLS Symptom From the 24-hour RLS Record Obtained at the End of Treatment (Week 12)
The time to onset of the first RLS symptoms from the 24-hour RLS Record is defined as the length of time from the start of the 24-hour assessment period (8:00 AM) to the time when 50% of participants experienced their first symptom.
Time frame: Week 12
Population: MITT Population. The number of participants assessed varies due to incomplete/missing data.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Placebo | Time to Onset of the First RLS Symptom From the 24-hour RLS Record Obtained at the End of Treatment (Week 12) | 12.8 hours |
| GEn (XP13512/GSK1838262) 1200 mg | Time to Onset of the First RLS Symptom From the 24-hour RLS Record Obtained at the End of Treatment (Week 12) | 13.5 hours |
| GEn (XP13512/GSK1838262) 1200 mg | Time to Onset of the First RLS Symptom From the 24-hour RLS Record Obtained at the End of Treatment (Week 12) | 13.8 hours |